Global rights to registrational-stage ophthalmology drug return to Molecular Partners Improvements in manufacturing and formulation have been made and tested in  pre-clinical models with the potential to overcome inflammatory side effects Ongoing research discovery alliance with AbbVie in

Ensovibep maintains potency in an in vitro assay and demonstrated full inhibition of all newly emerging known variants of concern, including the Delta variants of concern EMPATHY Phase 2/3 trial enrolling ambulatory patients in 5 countries with more countries to be added in the coming months, with

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 /  Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of

Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with COVID-19 Ensovibep receives U.S. FDA Fast Track Designation for the treatment of COVID-19 in both hospitalized and ambulatory settings ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 13, 2021

Zurich-Schlieren, Switzerland, June 9, 2021.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000

EMPATHY global multi-center Phase 2 – 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3 Novartis has been granted

in vitro  studies show ensovibep (MP0420) maintains full potency against the known mutations of SARS-CoV-2, including those present in variants first identified in Brazil, California, India, and New York, in addition to the previously reported variants originating from the UK and South Africa

Zurich-Schlieren, Switzerland, May 04, 2021.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021.

Zurich-Schlieren, Switzerland, April 23, 2021.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has filed a registration statement on Form F-1 with the

Zurich-Schlieren, Switzerland, April 21, 2021.  At today’s AGM of  Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, the shareholders of the company approved all motions proposed by the Board of